Generic Pluvicto Availability
Last updated on Nov 6, 2024.
Pluvicto is a brand name of lutetium lu 177 vipivotide tetraxetan, approved by the FDA in the following formulation(s):
PLUVICTO (lutetium lu-177 vipivotide tetraxetan - solution;intravenous)
-
Manufacturer: NOVARTIS
Approval date: March 23, 2022
Strength(s): 27mCi/ML [RLD]
Has a generic version of Pluvicto been approved?
No. There is currently no therapeutically equivalent version of Pluvicto available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pluvicto. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Patent 10,398,791
Issued: September 3, 2019
Inventor(s): Eder Matthias & Kopka Klaus & Schäfer Martin & Bauder-Wüst Ulrike & Haberkorn Uwe & Eisenhut Michael & Mier Walter & Benesova MartinaThe present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
Patent expiration dates:
- October 17, 2034✓✓
- October 17, 2034
-
PSMA binding ligand-linker conjugates and methods for using
Patent 10,406,240
Issued: September 10, 2019
Inventor(s): Low Philip S. & Kularatne Sumith A.
Assignee(s): Purdue Research FoundationDescribed herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
Patent expiration dates:
- August 15, 2028✓✓✓
- August 15, 2028
-
Patent 11,318,121
Patent expiration dates:
- August 15, 2028✓✓✓
- August 15, 2028
-
Patent 11,951,190
Patent expiration dates:
- November 12, 2035✓
- November 12, 2035
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- March 23, 2027 - NEW CHEMICAL ENTITY
More about Pluvicto (lutetium lu 177 vipivotide tetraxetan)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (3)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: therapeutic radiopharmaceuticals
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
